Abstract

This invention relates to methods of treating or preventing viral infections caused by flaviviruses, such as dengue virus, yellow fever virus, West Nile virus or Japanese encephalitis virus or infections caused by Chikungunya virus (CHIKV). The methods involve the administration of retinoic acid analogues to subjects who have, are suspected of having a flavivirus infection or infection with CHIKV, or to those who are at risk of becoming infected with a flavivirus or becoming infected with CHIKV.

IPC Classes  ?

• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/203 - Retinoic acids

Abstract

The invention relates to vaccine compositions for inducing an immune response to a coronavirus in a subject, and uses thereof. In particular, the vaccine comprises of a chimeric or fusion protein comprising a) a N-terminal secretion signal peptide; b) an amino acid sequence of the receptor binding domain (RBD) of a spike protein of a coronavirus; and c) a C-terminal domain comprising a transmembrane region and a cytoplasmic region. In a preferred embodiment, the signal peptide, RBD, transmembrane region, and cytoplasmic region are derived from SARS-CoV-2, and that the vaccine composition is formulated as a lipid nanoparticle (LNP).

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 37/04 - Immunostimulants
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Abstract

Stability to long term charge and discharge cycles is the most formidable challenge for Lithium-Sulfur batteries. Therefore, a more holistic design of a durable cathode with minimal polysulfide escape to mitigate the corrosion of the lithium anode is required. A saccharide-based binder system—the monosaccharide (glucose) component, on account of being a strong reducing agent has a unique capacity for the regulation of polysulfide thereby dramatically enhancing the functionality of a polysaccharide (carboxymethyl cellulose) binder system. The two-component binder system promotes the formation of viscoelastic filaments during casting which endows sulfur cathode a desired web-like microstructure. The combination of these effects leads to 97% sulfur utilisation with an ultra-long cycle life of 1000 cycles (9 months) and a high capacity retention (around 700 mAhg−1 after 1000 cycles). A pouch cell prototype with a capacity of 1200 mAhg−1 demonstrates a promising transition from laboratory to manufacturing options.

IPC Classes  ?

• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries

Abstract

Provided herein is a process for producing a compound of formula (I), or a salt thereof: (I) catalyst. Also provided herein are catalysts which find use in the process. Provided herein is a process for producing a compound of formula (I), or a salt thereof: (I) catalyst. Also provided herein are catalysts which find use in the process.

IPC Classes  ?

• C07C 51/15 - Preparation of carboxylic acids or their salts, halides, or anhydrides by reaction of organic compounds with carbon dioxide, e.g. Kolbe-Schmitt synthesis
• B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material
• B01J 37/08 - Heat treatment
• C07C 51/10 - Preparation of carboxylic acids or their salts, halides, or anhydrides by reaction with carbon monoxide

Abstract

The present invention provides a method of producing an artificial skin tissue that includes fibroblasts, keratinocytes, and a platelet-derived hydrogel, matured in serum- free media comprising platelet lysate, and methods of using the same.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 35/33 - Fibroblasts
• A61K 35/36 - SkinHairNailsSebaceous glandsCerumenEpidermisEpithelial cellsKeratinocytesLangerhans cellsEctodermal cells
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• A61L 27/38 - Animal cells
• A61L 27/52 - Hydrogels or hydrocolloids
• A61L 27/60 - Materials for use in artificial skin
• A61P 17/00 - Drugs for dermatological disorders
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

Provided herein is a catalyst-coated structured reactor, and a method of making such a reactor. Also provided herein is the use of such reactors in processes for producing chemical products, such as in the dry reforming of methane (DRM) process.

IPC Classes  ?

• B01J 8/02 - Chemical or physical processes in general, conducted in the presence of fluids and solid particlesApparatus for such processes with stationary particles, e.g. in fixed beds
• B01J 23/755 - Nickel
• C01B 3/26 - Production of hydrogen or of gaseous mixtures containing hydrogen by decomposition of gaseous or liquid organic compounds of hydrocarbons using catalysts

Abstract

The present invention relates to relates to peptide conjugates and uses thereof, particularly conjugates comprising a peptide and a superparamagnetic iron oxide nanoparticle (SPION), oral dosage forms comprising the same and uses thereof, for example, in the treatment of fibrosis and fibrosis-related diseases or conditions.

IPC Classes  ?

• A61K 47/52 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 38/22 - Hormones
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

A system including: a distance sensor system located/oriented/configured to measure a deformation of a geomaterial portion due to compaction of the geomaterial portion; and an electronic processing system configured to: receive signals from the distance sensor system representing the measured deformation, and automatically generate an estimate/measure of a geomaterial layer property of the geomaterial portion based on: the measured deformation; and a pre-defined relationship/model that associates deformation values with geomaterial layer property values (e.g., density values, stiffness values, modulus values, energy values, or layer thicknesses during compaction).

IPC Classes  ?

• E02D 1/02 - Investigation of foundation soil in situ before construction work
• E01C 23/01 - Devices or auxiliary means for setting-out or checking the configuration of new surfacing, e.g. templates, screed supportsApplications of apparatus for measuring, indicating, or recording the surface configuration of existing surfacing, e.g. profilographs
• G01B 21/32 - Measuring arrangements or details thereof, where the measuring technique is not covered by the other groups of this subclass, unspecified or not relevant for measuring the deformation in a solid

Abstract

An apparatus for use in promoting motility of flagellar cells includes an acoustic energy emission module configured to generate ultrasound energy, the module being configured to generate ultrasound waves within a frequency range of about 2 MHz and about 120 MHz, and an applicator module configured to direct the generated ultrasound waves to a locus of the cells for a duration of between about 5 seconds and about 35 seconds.

IPC Classes  ?

• A61N 7/00 - Ultrasound therapy
• C12N 5/076 - Sperm cellsSpermatogonia

Abstract

This invention relates to polypeptides, including variants of interleukin-38 (IL-38), and related therapeutics and compositions. The invention also relates to the use of the polypeptides and compositions in methods of treating inflammatory diseases or conditions. The present invention provides a monomeric polypeptide comprising an amino acid sequence of an IL-38 monomer, the amino acid sequence having a mutation or modification for preventing the peptide from forming a homodimer and favouring the formation of a stable monomer.

IPC Classes  ?

• C07K 14/54 - Interleukins [IL]
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli

Abstract

The invention relates to enzymes and polypeptide complexes for generating energy from hydrogen or for generating hydrogen, nucleic acid molecules encoding the same, devices and systems comprising the same, and uses thereof. An isolated, synthetic or purified nucleic acid molecule encoding a hydrogenase from archaea of a lineage Thermoplasmatota, Asgardarchaeota, Thermoproteota, EX4484-52, Aenigmarchaeota / QMZS01, Nanoarchaeota, Altarchaeota, lainarchaeota, or Micrarchaeota.

IPC Classes  ?

• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12P 3/00 - Preparation of elements or inorganic compounds except carbon dioxide
• H01M 8/16 - Biochemical fuel cells, i.e. cells in which microorganisms function as catalysts
• H01M 8/22 - Fuel cells in which the fuel is based on materials comprising carbon or oxygen or hydrogen and other elementsFuel cells in which the fuel is based on materials comprising only elements other than carbon, oxygen or hydrogen

Abstract

A method of screening candidate agents for their ability to modulate RAGE activity where such RAGE activity is induced by an active co-located GPCR, the method comprising the steps of: contacting a RAGE polypeptide with a GPCR polypeptide in the presence of a candidate agent where the GPCR polypeptide is constitutively active and/or is activated by addition of an agonist, partial agonist or allosteric modulator of that GPCR; and detecting whether the candidate agent is a modulator of RAGE ligand-independent activation of RAGE by activated co-located GPCR by detecting an effect indicative of modulation of RAGE activation by the presence of the candidate agent and/or by detecting RAGE-dependent signalling that is modulated by the presence of the candidate agent.

IPC Classes  ?

• C07K 14/72 - ReceptorsCell surface antigensCell surface determinants for hormones
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

The invention provides a capacitive energy storage device comprising: a lithium metal anode; a capacitive cathode comprising an ion-adsorption electrode material; an aprotic electrolyte comprising lithium salt; a nitrogen-based component selected from (i) a nitrogen oxide anion, present in the aprotic electrolyte, (ii) a reaction product of a nitrogen oxide anion, present in a solid electrolyte interphase layer between the lithium metal anode and the aprotic electrolyte, and (iii) combinations thereof; and a sulfur-based component selected from (i) a polysulfide anion, present in the aprotic electrolyte, (ii) a polysulfide anion or reaction product thereof, present in a solid electrolyte interphase layer between the lithium metal anode and the aprotic electrolyte, and (iii) combinations thereof.

IPC Classes  ?

• H01G 11/54 - Electrolytes
• H01G 4/005 - Electrodes
• H01G 11/08 - Structural combinations, e.g. assembly or connection, of hybrid or EDL capacitors with other electric components, at least one hybrid or EDL capacitor being the main component
• H01G 11/22 - Electrodes
• H01G 11/34 - Carbon-based characterised by carbonisation or activation of carbon
• H01G 11/36 - Nanostructures, e.g. nanofibres, nanotubes or fullerenes
• H01G 11/38 - Carbon pastes or blendsBinders or additives therein
• H01G 11/40 - Fibres
• H01G 11/42 - Powders or particles, e.g. composition thereof
• H01G 11/50 - Electrodes characterised by their material specially adapted for lithium-ion capacitors, e.g. for lithium-doping or for intercalation
• H01G 11/58 - Liquid electrolytes
• H01G 11/84 - Processes for the manufacture of hybrid or EDL capacitors, or components thereof

Abstract

The present application relates to CTLA4 fusion proteins, compositions comprising the same, and uses thereof, wherein the CTLA4 fusion proteins do not displace cis-bound PDL1 from B7 upon binding.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates generally to a method of detecting and/or analysing target polymers, especially target polynucleotides, using a biological pore. The invention also relates to a novel system for carrying out the method. The method has many uses. In particular, the method may be used for diagnosis, detection of polymorphisms and V(D)J repertoire analysis.

IPC Classes  ?

• G01N 27/327 - Biochemical electrodes
• C12Q 1/44 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving esterase
• C12Q 1/6825 - Nucleic acid detection involving sensors

Abstract

The present invention relates to methods and compositions for treating autoimmune or inflammatory disease characterised by an aberrant or inappropriate immune response to one or more of Ro60 protein; MPO protein; and Smith protein.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C07K 14/725 - T-cell receptors
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

The present invention relates to productive tissue repair and regeneration, and in particular fusion proteins, compositions including said fusion proteins, and methods of using said fusion proteins or compositions for productive tissue repair and regeneration. In one aspect, the invention provides fusion protein comprising: a NAMPT cytokine finger (cif) polypeptide and an Fc region of an antibody.

IPC Classes  ?

• C12N 9/10 - Transferases (2.)
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 21/06 - Anabolic agents
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates generally to methods and compositions for treating and/or preventing an inflammatory bowel disease (IBD) and perianal fistulas, the method comprising the administration of therapeutic cells in the subject in need thereof.

IPC Classes  ?

• A61K 35/50 - PlacentaPlacental stem cellsAmniotic fluidAmnionAmniotic stem cells
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Provided herein according to some embodiments a hybrid antibiotic molecule that may be resistant to multi-drug resistance. Dry powder and hydrogel formulations of the hybrid antibiotic molecules are disclosed. Also provided herein is a method of treating a bacterial infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the hybrid antibiotic molecule or a pharmaceutical composition comprising the hybrid antibiotic molecule, thereby treating the bacterial infection in the subject.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/33 - Heterocyclic compounds

Abstract

The present invention is directed to lipid nanoparticles, formulations containing lipid nanoparticles and methods of treating diseases or conditions with said lipid nanoparticles and formulations thereof. A lipid nanoparticle comprising (a) an active agent; (b) a cationic and/or ionisable lipid comprising from about 40 mol % to about 60 mol % of the total lipid present in the nanoparticle; (c) a phospholipid comprising from about 5 mol % to about 20 mol % of the total lipid present in the nanoparticle; (d) a structural lipid comprising from about 30 mol % to about 50 mol % of the total lipid present in the nanoparticle; (e) a PEGylated lipid comprising from about 0.05 mol % to less than 0.5 mol % of the total lipid present in the nanoparticle.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 37/08 - Antiallergic agents

Abstract

The present invention relates to new strains of Enterococcus sp., in particular, inflammatory and non-inflammatory strains of Enterococcus sp., useful for bacterio therapy.

IPC Classes  ?

• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• C12N 1/20 - BacteriaCulture media therefor
• C12R 1/46 - Streptococcus

Abstract

The invention relates to enzymes and polypeptide complexes for generating energy from hydrogen, nucleic acid molecules encoding the same, devices and systems comprising the same, and uses thereof.

IPC Classes  ?

• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 1/20 - BacteriaCulture media therefor
• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
• C12R 1/01 - Bacteria or actinomycetales

Abstract

There is disclosed a system including: a solar array configurable between a stored condition and a deployed condition; and at least one hanger member arranged to hang the solar array when in the stored condition, such that the solar array hangs down from the hanger member, wherein the hanger member includes a grippable portion for use during deployment of the solar array to the deployed condition.

IPC Classes  ?

• H02S 30/20 - Collapsible or foldable PV modules
• H02S 10/40 - Mobile PV generator systems
• H02S 20/30 - Supporting structures being movable or adjustable, e.g. for angle adjustment

Abstract

Disclosed herein is a method of biosensing nucleic acid analytes in samples, potentially complex biological samples, and the use of such methods in diagnostic applications. Also disclosed herein are diagnostic methods which use a voltametric biosensing device comprising a porous substrate comprising a plurality of channels, wherein at least a portion of the plurality of channels comprise moieties e.g., capture probes, which may be capable of binding with one or more nucleic acid analytes in complex biological samples.

IPC Classes  ?

• C12Q 1/6825 - Nucleic acid detection involving sensors
• B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 27/327 - Biochemical electrodes

Abstract

Deformable porous elastic conductors and fabrication methods thereof, as well as their use in a broad range of applications including electrodes, supercapacitors, antennae, and electrocatalysts, medical devices, soft electronic devices and wearable sensors.

IPC Classes  ?

• H01B 1/22 - Conductive material dispersed in non-conductive organic material the conductive material comprising metals or alloys
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/257 - Means for maintaining electrode contact with the body using adhesive means, e.g. adhesive pads or tapes
• A61B 5/28 - Bioelectric electrodes therefor specially adapted for particular uses for electrocardiography [ECG]
• C23C 18/16 - Chemical coating by decomposition of either liquid compounds or solutions of the coating forming compounds, without leaving reaction products of surface material in the coatingContact plating by reduction or substitution, i.e. electroless plating
• C23C 18/20 - Pretreatment of the material to be coated of organic surfaces, e.g. resins
• C23C 18/44 - Coating with noble metals using reducing agents
• C25B 3/07 - Oxygen containing compounds
• C25B 3/09 - Nitrogen containing compounds
• C25B 11/031 - Porous electrodes
• C25B 11/052 - Electrodes comprising one or more electrocatalytic coatings on a substrate
• C25B 11/057 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the substrate or carrier material consisting of a single element or compound
• C25B 11/081 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the element being a noble metal
• H01Q 1/36 - Structural form of radiating elements, e.g. cone, spiral, umbrella

Abstract

Embodiments relate generally to a method of determining blood oxygen saturation, comprising: receiving, at a computing device, a first bioimpedance (BImp) measurement signal of a patient of a first frequency, and a second bioimpedance measurement signal of a patient of a second frequency different from the first frequency; wherein, including, for each of the first and second BImp measurement signals, an arterial pulse wave representing impedance changes through an artery of the patient over time; filtering each of the first and second BImp measurement signals; performing, on the first and second filtered BImp measurement signals, feature point extraction to generate a plurality of arterial pulse wave features; determining phase shift information based on the plurality of arterial pulse wave features for each of the first and second BImp measurement signals; and determining, based on the determined phase shift information, a blood oxygen level and saturation percentage of the patient.

IPC Classes  ?

• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/053 - Measuring electrical impedance or conductance of a portion of the body
• H03H 7/01 - Frequency selective two-port networks
• H03H 7/12 - Bandpass or bandstop filters with adjustable bandwidth and fixed centre frequency

Abstract

The present invention relates to nanocomplexes (NCs) comprising a polysaccharide nanoparticle (NP) and a hormone selected from insulin, glucagon, or glucagon-like protein-1, and uses thereof for reducing the blood glucose level, in particular, for the treatment of diabetes.

IPC Classes  ?

• A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
• A61K 9/51 - Nanocapsules
• A61K 38/26 - Glucagons
• A61K 38/28 - Insulins
• A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Disclosed herein is a phenolic-graphene oxide composition comprising phenolic-graphene oxide having a carbon to oxygen (C:O) ratio of 2.1 or greater and 5 or less.

IPC Classes  ?

• B01D 71/06 - Organic material
• B01D 61/02 - Reverse osmosisHyperfiltration
• B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
• B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
• C02F 1/44 - Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis

Goods & Services

Computer apparatus for educational use; downloadable software, including educational software; educational science sets consisting of educational apparatus and simulators; interactive educational computer game software for use with television receivers; interactive educational computer game software for use with video apparatus; databases; downloadable mobile software applications (apps). Printed matter and printed publications including booklets, books, brochures, handbooks, manuals, magazines, newsletters, instructional and teaching material, policy submissions, scientific papers, articles. Research services relating to business including for the purpose of mitigating the environmental impact of business; advice and consultancy relating to business management and business planning including for the purpose of mitigating the environmental impact of business; compilation of environmental information; business data analysis services; business statistical analysis; business research including research for the purpose of mitigating the environmental impact of business; collecting business information, collecting business statistics; preparation of business reports and statistics including in relation to mitigating the environmental impact of business; business project management and administration; project studies for businesses; providing information, including online, about business management and administration including for the purpose of mitigating the environmental impact of business; compilation and provision of information relating to all of the foregoing services via printed materials and reports, publications and directories; information, advisory and consultancy services relating to all of the foregoing services, including such services being provided online or through podcasts, webcasts, social media, booklets, publications, and/or through downloadable mobile software applications (apps). Education services including in relation to the environment; education information including in relation to the environment; arranging and conducting exhibitions, seminars and conferences for educational purposes; advisory and consultancy services relating to education including environmental education; event management services (organization of educational and entertainment events); providing information, including online, about education, training and entertainment activities; provision of education services via an online forum; publication of books, texts and educational materials; museum services, including provision of museum facilities, conducting museum presentations and exhibitions; display of works of art (exhibitions, shows, museums, galleries); provision of information relating to education, training and entertainment via printed materials and reports, publications and directories; information, advisory and consultancy services relating to all of the foregoing services, including such services being provided online or through podcasts, webcasts, social media, booklets, publications, and/or through downloadable mobile software applications (apps). Provision of research services in the field of environment and environmental protection; management of scientific research projects; meteorological research; oceanographic research services; preparation of reports and statistics relating to scientific and technical research; preparation of technical projects, technical research and consultancy services in the field of carbon offsetting; providing information, including online, about scientific and technological services and research and design relating thereto; advisory and consultancy services relating to the environment including in relation to projects involving the environment and environmental protection; environmental hazard assessment; environmental monitoring services; environmental surveys; environmental testing; pollution emissions testing; conducting of environmental feasibility studies; online provision of non-downloadable web-based software; provision of information relating to the environment and scientific research via printed materials and reports, publications and directories; information, advisory and consultancy services relating to all of the foregoing services, including such services being provided online or through podcasts, webcasts, social media, booklets, publications, and/or through downloadable mobile software applications (apps).

Abstract

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

IPC Classes  ?

• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Abstract

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a provided lipid prodrug or a pharmaceutical composition thereof.

IPC Classes  ?

• A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Abstract

The invention provides methods and compositions for producing a multi-layered cellular structure or blastocyst-like structure from a cell population of reprogrammed somatic cells.

IPC Classes  ?

• C12N 5/074 - Adult stem cells

Abstract

Provided herein is a process for producing furfural from lignocellulosic biomass or an extract thereof, such as an extract rich in saccharides, using solid zinc sulfate-rich catalysts to catalyse conversion to furfural. Also provided herein are zinc sulfate-rich catalysts, and processes for producing zinc sulfate and zinc sulfate-rich catalysts from tyre char.

IPC Classes  ?

• C07D 307/48 - Furfural
• B01J 27/053 - Sulfates

Abstract

Disclosed herein is a method for co-pyrolysis of a polyolefin and a rubber containing material comprising: operating at least a pyrolysis stage of a pyrolysis reactor at an operating temperature at or above the temperature at which pyrolysis of both the polyolefin and the rubber containing material commences and up to about 600° C. under a substantially inert atmosphere; feeding a mixture comprising the polyolefin and the rubber containing material into the pyrolysis reactor; co-pyrolysing the mixture in the pyrolysis reactor to produce a pyrolysis gas comprising volatile pyrolysis products of the polyolefin and the rubber, wherein the volatile pyrolysis product of the olefin comprises at least a short chain olefin and the volatile product of the rubber comprises at least a diene; and facilitating a gas phase reaction between the short chain olefin and the diene to produce a volatile gas comprising single-ring aromatic hydrocarbons.

IPC Classes  ?

• C10B 53/07 - Destructive distillation, specially adapted for particular solid raw materials or solid raw materials in special form of synthetic polymeric materials, e.g. tyres

Abstract

Described herein is an imaging device (100) adapted to be incorporated into a device (200) for containing biological material (102). The imaging device (100) includes a sample holder (104) configured to hold a sample of the biological material (102). An input (106) is configured for receiving a beam of light (108). An illumination system (110)configured to convert the beam of light (108) into a two-dimensional sheet of light (112) and for directing the sheet of light (112) onto a target illumination zone (114). A transport mechanism (116) is adapted to move the target illumination zone (114) relative to the sample holder (104) such that the sheet of light (112) passes across the sample to illuminate the biological material (102). An imaging system (116) is positioned to receive at least a portion of the light returned from the biological material (102) and to direct the returned light onto an image sensor (120) to generate a plurality of images of the sample obtained at different positions of the sheet of light across the sample.

IPC Classes  ?

• G01N 21/64 - FluorescencePhosphorescence
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• C12M 1/00 - Apparatus for enzymology or microbiology
• G02B 21/00 - Microscopes

Abstract

A method and device for evaluating male fertility in a human or animal subject are provided. The device includes an acoustically-driven microfluidic rheometry instrument; a detector; and a processing device. The processing device is configured to determine thread thinning dynamics of a semen sample obtained from the subject, the thread thinning dynamics being determined using the instrument, wherein the thread thinning dynamics of the semen sample provide at least one measure indicative of a quality of sperm in the semen sample; compare the at least one measure with a minimum threshold reference value for determining male fertility in a human or animal subject; and evaluate fertility of the semen sample obtained from the subject based on the at least one measure.

IPC Classes  ?

• G01N 33/487 - Physical analysis of biological material of liquid biological material
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 1/10 - Devices for withdrawing samples in the liquid or fluent state
• G01N 15/00 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials
• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry

Abstract

The invention relates to the field of medical diagnostics. In particular, it relates to compositions, methods and kits for detecting immune cells for diagnosis of allergy, for monitoring of vaccination responses, for determining immune response to pathogens and of treatment efficacy of allergen immunotherapy. For example, the invention provides a method of determining allergic reactivity in a subject, the method comprising, providing a sample from a subject, contacting the sample with a recombinant or synthetic allergen linked to a detectable label in conditions for permitting the binding of the allergen to an IgE molecule present in the sample, determining the binding of the allergen to an IgE molecule in the sample by detecting the label, wherein the detection of the label indicates the subject has allergic reactivity. For example, the invention provides method of detecting antigen-specific B cells in a subject, the method comprising: providing a sample from a subject, contacting the sample with an antigen linked to a detectable label in conditions for permitting the binding of the antigen to an Ig molecule on the surface of a B cell present in the sample, and determining the binding of the antigen to an Ig molecule in the sample by detecting the label, wherein the detection of the label indicates the subject has antigen-specific B cells.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

An isolated or purified AON for modifying pre-mRNA splicing in the Receptor for Advanced Glycation End-products (RAGE) to modulate splicing of the RAGE gene transcript or part thereof is provided.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Dilute zinc alloys and processes for their manufacture are provided. The alloys contain iron and/or copper as major alloying metals and are prepared using hot extrusion and optional post-extrusion annealing. The alloys exhibit high strength and improved creep resistance. The alloys find particular, although not exclusive, use in the fabrication of biodegradable medical implants.

IPC Classes  ?

• C22F 1/16 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of other metals or alloys based thereon
• A61L 27/04 - Metals or alloys
• A61L 27/58 - Materials at least partially resorbable by the body
• A61L 31/02 - Inorganic materials
• A61L 31/14 - Materials characterised by their function or physical properties
• B21C 23/00 - Extruding metalImpact extrusion
• C22C 18/00 - Alloys based on zinc
• C22C 18/02 - Alloys based on zinc with copper as the next major constituent

Abstract

Disclosed herein is A process for producing levoglucosenone and/or chloromethylfurfural from biomass comprising cellulosic and/or hemicellulosic material, the process comprising subjecting the biomass to a first thermal treatment at a temperature of from about 200 °C to about 275 °C to form torrefied biomass and torrefaction gas; and subjecting the torrefied biomass to a second thermal treatment at a temperature of from about 300 °C to about 350 °C in the presence of an inorganic acid to form a pyrolysis gas comprising levoglucosenone and/or chloromethylfurfural.

IPC Classes  ?

• C10G 11/08 - Halides
• B01J 27/10 - Chlorides
• C07D 307/48 - Furfural
• C07D 493/08 - Bridged systems
• C10B 53/02 - Destructive distillation, specially adapted for particular solid raw materials or solid raw materials in special form of cellulose-containing material
• C10G 17/02 - Refining of hydrocarbon oils, in the absence of hydrogen, with acids, acid-forming compounds, or acid-containing liquids, e.g. acid sludge with acids or acid-containing liquids, e.g. acid sludge
• C10G 55/06 - Treatment of hydrocarbon oils, in the absence of hydrogen, by at least one refining process and at least one cracking process plural serial stages only including at least one catalytic cracking step

Abstract

Fluid drainage cannula, the cannula comprising an elongate tubular body having an annular wall which defines an internal lumen, the body extending between a distal end for insertion into a vessel of a subject and a proximal end for connection with an outlet hub; a tip portion of the body located at or about the distal end, the tip portion comprising a length of the body which includes one or more openings to facilitate the flow of fluids between the vessel and the lumen, wherein the lumen is of non-uniform diameter along at least a portion of the length of the tip portion.

IPC Classes  ?

• A61M 25/00 - CathetersHollow probes
• A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
• A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
• A61M 27/00 - Drainage appliances for wounds, or the like
• A61M 60/37 - Haemodialysis, haemofiltration or diafiltration

Abstract

The present disclosure is directed to human protease activated receptor 4 (PAR4) binding proteins (e.g. antibodies). In particular, anti-PAR4 binding proteins which are antagonists of human PAR4, as well as methods and uses thereof.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors

Abstract

The invention relates to CCR6, to antibodies and related fragments thereof for binding to said receptors, to production of said antibodies and fragments and to use of said antibodies and fragments for detection and therapy of various conditions, in particular autoimmune diseases, inflammation, infection, oncology and fibrosis.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 17/06 - Antipsoriatics
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons

Abstract

The present disclosure provides lipid compounds useful in treating inflammatory skin diseases.

IPC Classes  ?

• C07H 15/10 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical containing unsaturated carbon-to-carbon bonds
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61K 31/737 - Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate

Abstract

The present invention relates to chimeric and fusion proteins and their compositions, and the use of such proteins and compositions in the prevention and/or treatment diseases or conditions requiring plasminogen supplementation. In one aspect, the invention provides a chimeric or fusion protein comprising plasminogen and an Fc region of an antibody.

IPC Classes  ?

• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors
• C12N 9/68 - Plasmin, i.e. fibrinolysin
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

Disclosed herein is a process for producing nanosheet monolayers from a crystalline source material having a layered structure, the process comprising ball milling the crystalline source material with a liquid branched polymer having a viscosity at 20 ºC of at least 7000 mPas.

IPC Classes  ?

• B02C 17/18 - Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls Details
• B02C 17/00 - Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
• B82Y 40/00 - Manufacture or treatment of nanostructures
• C01B 21/06 - Binary compounds of nitrogen with metals, with silicon, or with boron
• C01B 21/064 - Binary compounds of nitrogen with metals, with silicon, or with boron with boron
• C01B 32/19 - Preparation by exfoliation
• C08G 12/08 - Amines aromatic
• C08G 83/00 - Macromolecular compounds not provided for in groups

Abstract

The invention relates to antigen binding proteins and related fragments thereof for binding to CCR8, to production of said antigen binding proteins and fragments and to use of said antigen binding proteins and fragments for detection and therapy of various conditions.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61P 37/02 - Immunomodulators

Abstract

The present invention relates to compositions, methods and kits for the treatment of fibrosis. In particular, the compositions, methods and kits are particularly useful, but not limited to, the treatment of cardiac fibrosis. The invention provides a method of treating fibrosis in an individual comprising administering an inhibitor of insulin-regulated aminopeptidase (IRAP), thereby treating fibrosis.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/4433 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

Provided herein are collections of compounds of formula a) to u), and salts thereof, which have polycyclic aromatic scaffolds and thus have structures targeted towards binding polynucleotide therapeutic targets, including polynucleotide-protein complexes. Also provided are compounds and salts themselves, methods of synthesizing such compounds, methods of identifying compounds having activity against a polynucleotide target, use of the compounds as reference compounds in assays, and phenotypic methods of identifying a new polynucleotide target using the compounds.

IPC Classes  ?

• C07D 495/04 - Ortho-condensed systems
• A61P 35/00 - Antineoplastic agents
• C07D 471/04 - Ortho-condensed systems
• C07D 493/04 - Ortho-condensed systems
• C07D 495/14 - Ortho-condensed systems

Abstract

The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
• A61K 31/365 - Lactones
• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• C07C 219/06 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
• C07C 235/36 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
• C07D 307/88 - Benzo [c] furansHydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
• A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
• C07C 271/24 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
• C07D 489/12 - Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
• C07J 1/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, not substituted in position 17 beta by a carbon atom, e.g. oestrane, androstane
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Methods of stimulating muscle regeneration, comprising delivering to a muscle a CCR5 interacting agent or encoding molecule. The CCR5 interacting agent binds to muscle stem cells and stimulates myoblast proliferation and muscle regeneration. One example of the CCR5 interacting agent is NAMPT comprising a cytokine finger motif or a derivative thereof. Methods and compositions include cellular compositions, which expresses the CCR5 interacting agent; including a population of satellite or macrophage cells or their precursors/progeny and their applications in stem cell therapy or for use in treating a muscular deficiency, disorder or injury. The examples show muscle tissue regeneration with minimal fibrosis. Also enabled is a NAMPT polypeptide fragment comprising a C-terminal portion of NAMPT comprising a cytokine finger. Compositions further comprise the NAMPT polypeptide fragment and one or more of; tissue stem cell or macrophage or precursor/progeny, scaffold or a retentive material, tissue delivery enhancing or cell retention moiety.

IPC Classes  ?

• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• A61K 38/45 - Transferases (2)
• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
• A61P 21/06 - Anabolic agents

Abstract

Apparatus including an optical signal generator, a data transmission path, and an optical signal receiver. Optical signal generator includes a coherent light source for generating a spectrum of carrier signals at different carrier frequencies, an optical demultiplexer that receives and separates the different carrier signals into separate optical paths, a pair of optical modulators located in each of the separate optical paths to modulate each different carrier signal with a data signal and produce an upper and lower sideband pair at each of the different carrier frequencies, and an optical interleaver to combine the upper and lower sideband pairs into an optical super-channel of interleaved sub-bands. Optical signal receiver includes a demodulator for extracting the data signals. Optical modulators are configured to reuse each carrier signal to transmit different data in each of the upper sideband and the lower sideband and increase the capacity of the super-channel. Also a method.

IPC Classes  ?

• H04B 10/50 - Transmitters
• H04B 10/516 - Details of coding or modulation
• H04B 10/61 - Coherent receivers
• H04J 14/02 - Wavelength-division multiplex systems

Abstract

This invention relates to methods of treating or preventing viral infections caused by flaviviruses, such as dengue virus, yellow fever virus, West Nile virus or Japanese encephalitis virus or infections caused by Chikungunya virus (CHIKV). The methods involve the administration of retinoic acid analogues to subjects who have, are suspected of having a flavivirus infection or infection with CHIKV, or to those who are at risk of becoming infected with a flavivirus or becoming infected with CHIKV.

IPC Classes  ?

• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/203 - Retinoic acids

Abstract

An interlayer for a lithium sulfur battery is provided. The interlayer is produced from an elastic polyelectrolyte liquid (EPL) and a two dimensional conducting material, such as graphene oxide. The EPL is produced from polyphenol, cationic polymer and facilitated ion transport protein. The interlayers are characterised by ion selective transport behaviour and electrocatalytic properties, and separator substrates coated with the interlayer may be usefully incorporated into lithium sulfur batteries.

IPC Classes  ?

• H01M 50/449 - Separators, membranes or diaphragms characterised by the material having a layered structure
• H01G 11/52 - Separators
• H01G 11/54 - Electrolytes
• H01M 10/052 - Li-accumulators
• H01M 10/0565 - Polymeric materials, e.g. gel-type or solid-type

Abstract

Described herein are peptides of formula (I) and pharmaceutical compositions and kits comprising the peptides. The use of the peptides in methods of treating or preventing diseases that are associated with modulation of Amyloid-beta protein-degrading proteases, such as neprilysin and angiotensin-converting enzyme 2, are also described.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Sulfur cathodes which include cellulosic compositions containing a plurality of anionically functionalised cellulose nanofibres are described. The anionically functionalised cellulose nanofibres are highly charged and have a low aspect ratio. The sulfur cathodes possess low porosity, high surface smoothness and facilitate the transport of Li ions while hindering the transport of polysulfide anions. Batteries employing the sulfur cathodes have high gravimetric and volumetric density.

IPC Classes  ?

• H01M 4/04 - Processes of manufacture in general
• D06M 11/30 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with halogensTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with halogen acids or salts thereofTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with oxides or oxyacids of halogens or salts thereof with oxides of halogens, oxyacids of halogens or their salts, e.g. with perchlorates
• D06M 13/352 - Heterocyclic compounds having five-membered heterocyclic rings
• D06M 101/06 - Vegetal fibres cellulosic
• H01G 11/24 - Electrodes characterised by structural features of the materials making up or comprised in the electrodes, e.g. form, surface area or porosityElectrodes characterised by the structural features of powders or particles used therefor
• H01G 11/36 - Nanostructures, e.g. nanofibres, nanotubes or fullerenes
• H01M 4/02 - Electrodes composed of, or comprising, active material
• H01M 4/139 - Processes of manufacture
• H01M 4/36 - Selection of substances as active materials, active masses, active liquids
• H01M 4/583 - Carbonaceous material, e.g. graphite-intercalation compounds or CFx
• H01M 10/052 - Li-accumulators

Abstract

An isolated or purified antisense oligomer for modifying pre-mRNA splicing in the Angiotensin Converting Enzyme 2 (ACE2) to modulate splicing of the ACE2 gene transcript or part thereof which has a modified backbone structure and sequences with at least 75% sequence identity to such antisense oligomers and which have a modified backbone structure.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention provides compounds of Formula (I), which have activity as inhibitors of MERTK. The present invention also provides radio-labelled compounds which may be used in diagnostic and imaging compositions. The present invention also provides methods and uses of the compounds in imaging body tissue, as well as identifying and diagnosing disease states. The present invention further provides methods and uses of the compounds in the treatment of diseases, particularly conditions and diseases associated with MERTK.

IPC Classes  ?

• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 51/04 - Organic compounds
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Disclosed herein is a structure comprising a substrate having a polycrystalline transition metal di-chalcogenide nanolayer disposed on a substrate surface, wherein the polycrystalline transition metal di-chalcogenide nanolayer has a surface, and a portion of the plurality of grains project out of plane from the surface.

IPC Classes  ?

• B82Y 40/00 - Manufacture or treatment of nanostructures
• C23C 14/02 - Pretreatment of the material to be coated
• C23C 14/06 - Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material characterised by the coating material
• C23C 14/16 - Metallic material, boron or silicon on metallic substrates or on substrates of boron or silicon
• C23C 14/18 - Metallic material, boron or silicon on other inorganic substrates
• C23C 14/54 - Controlling or regulating the coating process
• C23C 14/58 - After-treatment
• H01L 21/02 - Manufacture or treatment of semiconductor devices or of parts thereof

Abstract

Provided herein are aryl hydantoin compounds having the structure of Formula (I) wherein X, R1, R2, R3, R4e.ge.g., Schistosomiasis).

IPC Classes  ?

• A61K 31/4164 - 1,3-Diazoles
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61P 33/12 - Schistosomicides
• C07D 233/76 - Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom

Abstract

The present invention relates to the field of medical diagnostics. In particular, it relates to methods and kits for determining treatment efficacy of allergen immunotherapy, and for measuring or detecting biomarkers in a subject undergoing allergen immunotherapy. For example, the invention provides a method of determining efficacy of an allergen immunotherapy in a subject, the method comprising: providing a first sample obtained from a subject before receiving allergen immunotherapy; providing a second sample obtained from the subject who has received, or who is receiving, allergen immunotherapy; wherein the first and second samples comprise B-cells; and determining the level or amount of one or more biomarkers in B-cells, preferably allergen-specific B-cells, in the first and second samples, wherein the biomarkers are selected from the group consisting of IgE, CD29, CD69, IL13Rα, CD99, IgD, CXCR4, FCRL3, FCRL2, FCRL5, SIGLEC10, CD1c, CD23, and IL4Rα; wherein an increase in the level or amount of one or more biomarkers selected from IgE, CD29, IL13Rα, CD99, FCRL3, FCRL2, SIGLEC10, CD1c, CD23, and IL4Rα in B-cells in the second sample compared to the first sample indicates efficacy of an allergen immunotherapy in a subject, and/or wherein a decrease in the level or amount of one or more biomarkers selected from CD69, IgD, CXCR4, FCRL3, FCRL2, FCRL5, CD1c, CD23, IL4Rα in B- cells in the second sample compared to the first sample indicates efficacy of an allergen immunotherapy in a subject.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention relates to Clec9A, to antigen binding proteins and related fragments thereof for binding to Clec9A, to production of said antigen binding proteins and fragments and to use of said antibodies and fragments for detection and therapy of various conditions, in particular inflammation, infection and oncology.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• A61P 37/02 - Immunomodulators
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The invention relates to devices and methods for processing decision data, the decision data comprising a decision tree (T) and an input path (P), each node (r) of the decision tree being associated with a respective feature (i) of a feature set (F). According to the disclosure, the method comprises at least one iteration of an inheritance processing, as a function of a current universal set (U), representing some features which could be irrelevant to explain the input path, the set (U) being included in the feature set (F) and as a function of a current node (r) and a child node (s) linked together by an edge ((r,s)), the inheritance processing comprising: - determining that the edge ((r,s)) verifies a first criterion relative to a consistency of the edge ((r,s)) with a corresponding edge ((r',s')) of the input path (P) relative to the same feature (i) as those of the current node (r), and then performing a first sub-inheritance processing as a function of the child node (s); and/or - determining that the edge ((r,s)) verifies a second criterion, and then performing a second sub- inheritance processing as a function of the child node (s) and the current universal set (U), such that the first sub-inheritance processing and the second sub-inheritance processing allows including features in the set (U) for explaining the input path (P).

IPC Classes  ?

• G06N 5/01 - Dynamic search techniquesHeuristicsDynamic treesBranch-and-bound
• G06N 5/04 - Inference or reasoning models

Abstract

The present invention relates to β-peptides and hydrogels comprising the β-peptides. The hydrogels may further comprise a therapeutic cargo encapsulated within the hydrogel. Methods of preparing the hydrogels, and methods for the use of the hydrogels are also described.

IPC Classes  ?

• C07K 5/02 - Peptides having up to four amino acids in a fully defined sequenceDerivatives thereof containing at least one abnormal peptide link
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/06 - OintmentsBases therefor
• A61L 27/22 - Polypeptides or derivatives thereof
• A61L 27/52 - Hydrogels or hydrocolloids
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• C07K 5/09 - Tripeptides the side chain of the first amino acid containing more amino groups than carboxyl groups, or derivatives thereof, e.g. Lys, Arg
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 19/00 - Hybrid peptides

Abstract

An aluminium based alloy, and a method for production of components by additive manufacturing (AM) or other rapid solidification process with the alloy, is based on the alloy having a composition with from 2.01 wt % to 15.0 wt % manganese, from 0.3 wt % to 2.0 wt % scandium, with a balance apart from minor alloy elements and incidental impurities of aluminium.

IPC Classes  ?

• C22C 1/04 - Making non-ferrous alloys by powder metallurgy
• B22F 3/24 - After-treatment of workpieces or articles
• B22F 10/28 - Powder bed fusion, e.g. selective laser melting [SLM] or electron beam melting [EBM]
• B22F 10/64 - Treatment of workpieces or articles after build-up by thermal means
• B22F 12/20 - Cooling means
• B33Y 70/00 - Materials specially adapted for additive manufacturing
• C22C 21/00 - Alloys based on aluminium
• C22F 1/00 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working
• C22F 1/04 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of aluminium or alloys based thereon

Abstract

The present invention generally relates to methods of activating cells via the inhibition of PTP1B and PTPN2 for use in therapy. For example, the invention relates to preparing cells ex vivo for use in immunotherapy, particularly cancer immunotherapy. More specifically, the invention relates to methods for the preparation of leukocytes, particularly T cells, exhibiting cytotoxic properties for use in adoptive cell transfer. The invention also relates to cells and compositions including them for cancer immunotherapy. The invention also relates to methods of immunotherapy, particularly cancer immunotherapy.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to methods and uses for producing an insulin-producing cell from a pancreatic exocrine cell comprising contacting the pancreatic exocrine cell with an inhibitor of EZH2. The present invention also relates to methods and uses for preventing or treating a disease involving dysfunctional insulin production.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/365 - Lactones
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 35/39 - PancreasIslets of Langerhans
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 5/50 - Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
• C07C 331/20 - Isothiocyanates having isothiocyanate groups bound to acyclic carbon atoms of a saturated carbon skeleton
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 493/22 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
• C07J 63/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms

Abstract

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

IPC Classes  ?

• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Abstract

The invention provides a method of oxidising an inorganic amine to nitrate, the method comprising: contacting an aqueous solution comprising at least one inorganic amine selected from ammonia and haloamine with a titanium dioxide photocatalyst; and irradiating the aqueous solution with light, thereby photocatalytically oxidising at least a portion of the inorganic amine to nitrate, wherein the titanium dioxide photocatalyst is contacted with at least one phosphorous-based species before or during the oxidising.

IPC Classes  ?

• C01C 1/18 - Nitrates of ammonium
• B01J 21/06 - Silicon, titanium, zirconium or hafniumOxides or hydroxides thereof
• B01J 23/42 - Platinum
• B01J 23/50 - Silver
• B01J 23/52 - Gold
• B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
• B01J 37/08 - Heat treatment
• C05B 7/00 - Fertilisers based essentially on alkali or ammonium orthophosphates
• C05G 5/23 - Solutions

Abstract

Provided herein are compounds of Formula (I) that are dual inhibitors of kinases and bromo-domain proteins. The disclosure also relates to pharmaceutical compositions containing such compounds, methods for using such compounds in the treatment of cancers, particularly, the treatment of multiple myeloma cancers, and to related uses.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• C07D 495/04 - Ortho-condensed systems
• C07D 471/04 - Ortho-condensed systems
• A61P 35/00 - Antineoplastic agents

Abstract

A surgical system for use in establishing and maintaining an opening to an anatomical space of a body, the system comprising an obturator assembly having a cutting portion at a distal end and a cannula, the cannula being detachably coupled to the cutting portion and deployable into the anatomical space of a patient, the cannula comprises a locking portion, and a lengthwise extendable body; a valve assembly comprising a passage for receiving the cannula, a first end for coupling to a fluid extraction device and a second end for placement external and adjacent the anatomical space; a base comprising a plate for placement on a patient external and adjacent the anatomical space, the plate has an aperture configured for receiving the obturator assembly and coupling means located about the aperture for coupling with the valve assembly; and wherein, in use, the locking portion of the cannula is configured to be retained in the valve assembly with the extendable body extended into the anatomical space to facilitate a path for fluid extraction, and wherein the cannula comprises means for retaining the cannula in its extended state.

IPC Classes  ?

• A61M 1/04 - Pneumothorax apparatus
• A61B 17/34 - TrocarsPuncturing needles

Abstract

A method of making a polyelectrolyte complex membrane separator for a Lithium-Sulfur battery to support lean electrolyte operation, comprising the steps of: forming polyelectrolyte complex nanoparticles by the addition of polyethylenimine (PEI) to tannic acid (TA); adding bovine serum albumin (BSA); purifying the nanoparticles; re-dispersing the nanoparticles in water to form a nanoparticle suspension; and dipcoating a polyolefin membrane in the nanoparticle suspension.

IPC Classes  ?

• H01M 50/497 - Ionic conductivity
• H01M 50/403 - Manufacturing processes of separators, membranes or diaphragms
• H01M 50/417 - Polyolefins
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• B82Y 40/00 - Manufacture or treatment of nanostructures
• H01M 10/052 - Li-accumulators

Abstract

The present invention relates to compositions and methods for the treatment of lupus, particularly systemic lupus erythematosus. The present invention involves, amongst other things, a binding protein comprising a T cell receptor (TCR) α-chain variable (Vα or Valpha) domain and a TCR β-chain variable (Vβ or Vbeta) domain, wherein the binding protein is capable of binding to a complex of a fragment of a Smith protein and an HLA-DR15 or HLA-DR3 molecule.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

The present invention provides a fusion protein comprising interleukin-1 receptor antagonist (IL-1Ra) and an extracellular matrix (ECM) binding peptide which specifically binds to one or more or all extracellular matrix proteins selected from the group consisting of fibrinogen, fibronectin, vitronectin, tenascin C and heparan sulfate and use of the fusion protein to treat conditions in which administration of IL-1Ra is beneficial or in which IL-1R1 signalling needs to be dampened, to enhance tissue regeneration, particularly bone regeneration and/or wound repair or for treating wounds, burns and muscle, cartilage, tendon and bone disorders, to enhance the regenerative activity of growth factor administration or to reduce inflammation or desensitisation of a cell to growth factor stimulation.

IPC Classes  ?

• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
• C07K 14/475 - Growth factorsGrowth regulators
• C12N 15/62 - DNA sequences coding for fusion proteins
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators

Abstract

The invention provides a method of continuous electrochemical dinitrogen reduction to produce ammonia, the method comprising: supplying dinitrogen to an electrochemical cell comprising an electrolyte in contact with at least a cathode; introducing protons to the electrolyte by anodic oxidation of a hydrogen-containing species; and cathodically reducing the dinitrogen in the presence of a metal selected from lithium, magnesium, calcium, strontium, barium, zinc, aluminium and vanadium to produce ammonia, wherein the electrolyte comprises a cationic proton carrier capable of reversible deprotonation to form a neutral proton acceptor, wherein the neutral proton acceptor is an ylide.

IPC Classes  ?

• C25B 1/27 - Ammonia
• C01C 1/02 - Preparation or separation of ammonia
• C25B 1/50 - Processes
• C25B 9/05 - Pressure cells
• C25B 9/19 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms
• C25B 15/08 - Supplying or removing reactants or electrolytesRegeneration of electrolytes
• C25B 15/029 - Concentration

Abstract

A method of fault location in an electrical power line system (PLS), the method including: receiving at least one observed signal caused by a real fault in the PLS, wherein the or each observed signal is measured at a real observation point in the PLS, and wherein the real fault has occurred at one of two or more real locations in the PLS; accessing a library representing a plurality of model signals between model guessed fault locations and at least one model observation point in a network model of the PLS; selecting at least one of the model GFLs by: (i) calculating metrics for the model signals by processing the model signals with the or each observed signal according to a pre-selected mathematical relationship/operation, and/or (ii) selecting the at least one model GFL corresponding to at least one highest one of the calculated metrics; estimating at least one fault location of the two or more real locations in the PLS based on at least one corresponding location of the at least one selected model GFL; and sending the or each estimated fault location to an external management system to respond to the real fault.

IPC Classes  ?

• G01R 31/08 - Locating faults in cables, transmission lines, or networks
• G01R 31/50 - Testing of electric apparatus, lines, cables or components for short-circuits, continuity, leakage current or incorrect line connections
• G05B 23/02 - Electric testing or monitoring
• H02H 7/26 - Sectionalised protection of cable or line systems, e.g. for disconnecting a section on which a short-circuit, earth fault, or arc discharge has occurred

Abstract

The present disclosure generally relates to a method for reducing the toxicity of inhaled polymyxins as a therapeutic agent comprising the step of co-administration of an aminoglycoside; a method for improving the aerosolization of an aminoglycoside comprising the step of combination formulation with a polymyxin; and a process for manufacturing a dry powder composition comprising a polymyxin and aminoglycoside. Pharmaceutical compositions and methods of treatment for lung infections are within the scope of this invention.

IPC Classes  ?

• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61P 31/04 - Antibacterial agents
• A61K 38/12 - Cyclic peptides
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The invention also relates to antigen binding proteins and related fragments thereof for binding Von Willebrand factor (VWF) and uses thereof. In one aspect, the present invention provides an antigen binding protein comprising an antigen binding domain that binds to or specifically binds to Von Willebrand factor (VWF) under shear gradient conditions. Preferably, the antigen binding protein comprises an antigen binding domain that does not bind to VWF under constant shear conditions.

IPC Classes  ?

• C07K 16/36 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors

Abstract

The present invention provides an antigen binding protein comprising an antigen binding domain that binds to plasmin, wherein the antigen binding protein reduces the activity of plasmin. The invention also provides compositions comprising the antigen binding protein, and uses and method of treatment comprising the same.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid

Abstract

The invention provides a method for detecting one or more analytes, the method comprising: providing a substrate comprising a semiconductor with a porous surface, wherein the porous surface is coated with a fluorocarbon polymeric coating; contacting the porous surface with a fluid or object so that the one or more analytes are retained on the substrate when present in the fluid or on the object; and analysing the substrate by mass spectrometry to detect the one or more analytes if present on the substrate.

IPC Classes  ?

• G01N 27/623 - Ion mobility spectrometry combined with mass spectrometry
• H01J 49/04 - Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locksArrangements for external adjustment of electron- or ion-optical components
• H01L 21/02 - Manufacture or treatment of semiconductor devices or of parts thereof

Abstract

The invention provides a zwitterionic plastic crystal (ZIPC) compound in the form of a single molecule comprising: at least one positively charged functional group carrying at least one positive charge, and at least one negatively functional group carrying at least one negative charge, wherein the positively charged functional groups and the negatively charged functional groups are covalently tethered together in the molecule, and the net charge of the zwitterionic compound is zero, and wherein the compound exhibits evidence of molecular disorder in the solid state.

IPC Classes  ?

• H01M 10/0564 - Accumulators with non-aqueous electrolyte characterised by the materials used as electrolytes, e.g. mixed inorganic/organic electrolytes the electrolyte being constituted of organic materials only
• H01M 10/052 - Li-accumulators
• H01M 10/054 - Accumulators with insertion or intercalation of metals other than lithium, e.g. with magnesium or aluminium

Abstract

An additive manufacturing system and method is provided for fabricating 3D objects (16) from successive layers (14) of material. The additive manufacturing system (10) has an energy projection assembly (20) for inputting energy (22) into a specified area within the layer (18) to consolidate the material; a plurality of image sensors (30, 32, 34), each of the image sensors having a corresponding field of view (35, 40, 42) covering at least part of the layer (18) of material, such that each of the fields of view at least partially overlap with the field of view of at least one other of the image sensors; and an image processor (56) to capture image data from each of the image sensors (30, 32, 34). The image processor (56) controls exposure times for each of the image sensors (30, 32, 34) and combines the image data from the image sensors to provide a single, spatially resolved image of the energy being input throughout the specified area for each layer (14) of material respectively for comparison against threshold data values to locate potential consolidation defects in the specified area.

IPC Classes  ?

• B29C 64/393 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes
• B33Y 10/00 - Processes of additive manufacturing
• B22F 10/00 - Additive manufacturing of workpieces or articles from metallic powder
• B22F 10/28 - Powder bed fusion, e.g. selective laser melting [SLM] or electron beam melting [EBM]
• B22F 12/90 - Means for process control, e.g. cameras or sensors
• B22F 10/364 - Process control of energy beam parameters for post-heating, e.g. remelting
• B22F 10/366 - Scanning parameters, e.g. hatch distance or scanning strategy
• B22F 10/38 - Process control to achieve specific product aspects, e.g. surface smoothness, density, porosity or hollow structures
• B22F 10/85 - Data acquisition or data processing for controlling or regulating additive manufacturing processes

Abstract

Embodiments relate generally to a robotic fruit picking apparatus and a method of picking fruit. An example apparatus includes: a chassis; a robotic arm supported by the chassis and having an end effector, wherein the end effector includes a plurality of grippers and an extendable suction element; a vision system carried by the chassis and configured to identify pieces of fruit for picking; and a control system carried by the chassis and in communication with the vision system to control the robotic arm to pick identified pieces of fruit using the end effector. The control system may be configured to operate in a first mode to control the extendable suction element to extend the suction element towards a piece of fruit. The control system may be further configured to operate in a second mode following the first mode to retain contact with the piece of fruit by applying suction while freely allowing extension or retraction of the suction element based on movement of the piece of fruit.

IPC Classes  ?

• A01D 46/30 - Robotic devices for individually picking crops
• A01D 46/00 - Picking of fruits, vegetables, hops, or the likeDevices for shaking trees or shrubs
• A01D 46/24 - Devices for picking apples or like fruit
• B25J 15/06 - Gripping heads with vacuum or magnetic holding means
• B25J 15/08 - Gripping heads having finger members
• B25J 15/10 - Gripping heads having finger members with three or more finger members
• B25J 15/12 - Gripping heads having finger members with flexible finger members
• G06V 20/68 - Food, e.g. fruit or vegetables

Abstract

The present invention relates to polypeptides, particularly fusion protein variants comprising interleukin-37 (IL-37) and related therapeutics and compositions thereof. More particularly, the invention relates to fusion proteins comprising a mutant IL-37 polypeptide and an Fc region of an antibody. The biophysical stability such as thermal stability of said fusion proteins can be improved compared to a reference IL-37 construct, such as a wild-type IL-37 polypeptide or a mutant variant of an IL-37 polypeptide. It also relates to the fusion polypeptide variants and compositions for use in treating inflammatory diseases or conditions. In addition, the present invention relates to nucleic acid molecules encoding such fusion proteins, and vectors and host cells comprising such nucleic acid molecules.

IPC Classes  ?

• C07K 14/54 - Interleukins [IL]
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

A system including: a distance sensor system located/oriented/configured to measure a deformation of a geomaterial portion due to compaction of the geomaterial portion; and an electronic processing system configured to: receive signals from the distance sensor system representing the measured deformation, and automatically generate an estimate/measure of a geomaterial layer property of the geomaterial portion based on: the measured deformation; and a pre-defined relationship/model that associates deformation values with geomaterial layer property values (e.g., density values, stiffness values, modulus values, energy values, or layer thicknesses during compaction).

IPC Classes  ?

• G01B 21/32 - Measuring arrangements or details thereof, where the measuring technique is not covered by the other groups of this subclass, unspecified or not relevant for measuring the deformation in a solid
• E02D 1/02 - Investigation of foundation soil in situ before construction work
• G01B 11/06 - Measuring arrangements characterised by the use of optical techniques for measuring length, width, or thickness for measuring thickness
• G01B 11/16 - Measuring arrangements characterised by the use of optical techniques for measuring the deformation in a solid, e.g. optical strain gauge
• G01B 21/08 - Measuring arrangements or details thereof, where the measuring technique is not covered by the other groups of this subclass, unspecified or not relevant for measuring length, width, or thickness for measuring thickness
• G01N 3/00 - Investigating strength properties of solid materials by application of mechanical stress
• G01N 9/00 - Investigating density or specific gravity of materialsAnalysing materials by determining density or specific gravity
• G01N 33/24 - Earth materials

Abstract

The present invention is directed to an apparatus for separating micro-swimmers. The apparatus comprises a chamber having an inlet sub-chamber and an outlet sub-chamber, a plurality of microchannels disposed between the inlet sub-chamber and the outlet sub-chamber, a passage control mechanism for controlling the passage of micro-swimmers from the inlet sub-chamber to the outlet sub-chamber via the microchannels. The passage control mechanism is configurable to operate in a first condition in which passage of micro-swimmers from the inlet sub-chamber to the outlet sub-chamber are prevented, and a second condition in which passage of micro-swimmers from the inlet sub-chamber to the outlet sub-chamber via the microchannels are permitted.

IPC Classes  ?

• G01N 1/28 - Preparing specimens for investigation
• G01N 15/10 - Investigating individual particles
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• A61B 17/43 - Gynaecological or obstetrical instruments or methods for reproduction or fertilisation for artificial insemination

Abstract

An apparatus for use in promoting motility of flagellar cells, comprising an acoustic energy emission module configured to generate ultrasound energy, the module being configured to generate ultrasound waves within a frequency range of about 2 MHz and about 120 MHz; and an applicator module configured to direct the generated ultrasound waves to a locus of the cells for a duration of between about 5 seconds and about 35 seconds.

IPC Classes  ?

• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave
• A61N 7/00 - Ultrasound therapy
• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
• C12N 5/076 - Sperm cellsSpermatogonia
• C12N 13/00 - Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers

Abstract

The present disclosure generally relates to an interlayer for an electrochemical cell. The present disclosure also relates to porous interlayers comprising a carbon material and porous particles, and to a process for preparing the interlayers. The present disclosure also relates to energy storage devices comprising the interlayers and to use of the interlayers in energy storage devices, in particular lithium-sulfur (Li-S) batteries or vanadium redox flow batteries (VRFBs).

IPC Classes  ?

• H01M 50/414 - Synthetic resins, e.g. .thermoplastics or thermosetting resins
• H01M 8/0239 - Organic resinsOrganic polymers
• H01M 8/18 - Regenerative fuel cells, e.g. redox flow batteries or secondary fuel cells
• H01M 8/241 - Grouping of fuel cells, e.g. stacking of fuel cells with solid or matrix-supported electrolytes
• H01M 10/052 - Li-accumulators
• H01M 50/443 - Particulate material
• H01M 50/497 - Ionic conductivity

Abstract

This invention relates to polypeptides, including variants of interleukin-38 (IL-38), and related therapeutics and compositions. The invention also relates to the use of the polypeptides and compositions in methods of treating inflammatory diseases or conditions. The present invention provides a monomeric polypeptide comprising an amino acid sequence of an IL-38 monomer, the amino acid sequence having a mutation or modification for preventing the peptide from forming a homodimer and favouring the formation of a stable monomer.

IPC Classes  ?

• C07K 14/54 - Interleukins [IL]
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/20 - Interleukins
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

Provided herein are metal-organic framework (MOF) biocomposites, in particular biocomposites comprising partially embedded biomolecules such as antibodies. Also provided herein are methods of producing the MOF biocomposites, and uses of the MOF biocomposites in applications such as imaging, sensing and detection, diagnosis and therapy.

IPC Classes  ?

• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 33/26 - IronCompounds thereof
• A61K 47/02 - Inorganic compounds
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
• A61K 9/51 - Nanocapsules
• C07K 9/00 - Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequenceDerivatives thereof
• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/44 - Antibodies bound to carriers
• A61P 35/00 - Antineoplastic agents
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes

Abstract

Described embodiments generally relate to a method for improving data accuracy of sleep pattern data. The method comprises receiving first data relating to at least one sleep pattern metric; receiving second data relating to the at least one sleep pattern metric, wherein the second data is data entered by a user; determining the difference between the first data and the second data to calculate a data infidelity value; and in response to the data infidelity value exceeding a predetermined threshold, prompting a user to enter third data relating to at least one metric.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires

Abstract

Disclosed herein is A structure comprising: a top gate electrode and a bottom gate electrode, a channel layer formed from a channel material with a band gap modulable by electric field, the channel layer being electrically insulated from the top gate electrode and the bottom gate electrode and being located adjacent to at least one layer of a negative capacitance material.

IPC Classes  ?

• H01L 27/088 - Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including integrated passive circuit elements with at least one potential-jump barrier or surface barrier the substrate being a semiconductor body including only semiconductor components of a single kind including field-effect components only the components being field-effect transistors with insulated gate
• H01L 29/51 - Insulating materials associated therewith
• H01L 29/745 - Gate-turn-off devices with turn-off by field effect
• H01L 29/78 - Field-effect transistors with field effect produced by an insulated gate
• H01L 29/92 - Capacitors with potential-jump barrier or surface barrier
• H03K 17/30 - Modifications for providing a predetermined threshold before switching

Abstract

Disclosed herein is A structure comprising: a top gate electrode and a bottom gate electrode, a channel layer formed from a channel material with a band gap modulable by electric field, the channel layer being electrically insulated from the top gate electrode and the bottom gate electrode and being located adjacent to at least one layer of a negative capacitance material.

IPC Classes  ?

• H03K 17/30 - Modifications for providing a predetermined threshold before switching
• H01L 27/088 - Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including integrated passive circuit elements with at least one potential-jump barrier or surface barrier the substrate being a semiconductor body including only semiconductor components of a single kind including field-effect components only the components being field-effect transistors with insulated gate
• H01L 27/108 - Dynamic random access memory structures
• H01L 29/51 - Insulating materials associated therewith
• H01L 29/66 - Types of semiconductor device
• H01L 29/745 - Gate-turn-off devices with turn-off by field effect
• H01L 29/78 - Field-effect transistors with field effect produced by an insulated gate
• H01L 29/92 - Capacitors with potential-jump barrier or surface barrier
• H01L 49/00 - Solid state devices not provided for in groups and and not provided for in any other subclass; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof

Abstract

The present invention relates to productive tissue repair and regeneration, and in particular poylpeptides, compositions including said polypeptides, and methods of using said polypeptides or compositions for productive tissue repair and regeneration. In one aspect, the invention provides a polypeptide comprising, consisting essentially of or consisting of a C-terminal portion of NAMPT comprising a truncated cytokine finger motif (cif) motif. In another aspect, the present invention provides a fusion protein comprising, consisting essentially of or consisting of a polypeptide of a full length NAMPTcif or truncated variants and a tissue delivery or retention enhancing moiety.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/45 - Transferases (2)
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/00 - Drugs for immunological or allergic disorders
• C12N 9/10 - Transferases (2.)

Abstract

The present invention relates to productive tissue repair and regeneration, and in particular poylpeptides, compositions including said polypeptides, and methods of using said polypeptides or compositions for productive tissue repair and regeneration. In one aspect, the invention provides a polypeptide comprising, consisting essentially of or consisting of a C-terminal portion of NAMPT comprising a truncated cytokine finger motif (cif) motif. In another aspect, the present invention provides a fusion protein comprising, consisting essentially of or consisting of a polypeptide of a full length NAMPTcif or truncated variants and a tissue delivery or retention enhancing moiety.

IPC Classes  ?

• C12N 9/10 - Transferases (2.)
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/45 - Transferases (2)
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The present application relates to CTLA4 fusion proteins, compositions comprising the same, and uses thereof, wherein the CTLA4 fusion proteins do not displace cis-bound PDL1 from B7 upon binding.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 15/867 - Retroviral vectors
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to modified T cell receptors and their uses in treating various diseases or conditions, particularly cancer and autoimmune diseases. A binding protein comprising a variable domain comprising a complementarity-determining region (CDR) capable of contacting a peptide bound to an HLA molecule, wherein the CDR 5 comprises a cysteine capable of forming a disulphide bond with a cysteine in the peptide bound to the HLA molecule, typically wherein the cysteine is introduced into the CDR by mutation or modification of an existing residue.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 38/00 - Medicinal preparations containing peptides
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/725 - T-cell receptors
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 15/79 - Vectors or expression systems specially adapted for eukaryotic hosts

Abstract

The present invention relates to modified T cell receptors and their uses in treating various diseases or conditions, particularly cancer and autoimmune diseases. A binding protein comprising a variable domain comprising a complementarity-determining region (CDR) capable of contacting a peptide bound to an HLA molecule, wherein the CDR 5 comprises a cysteine capable of forming a disulphide bond with a cysteine in the peptide bound to the HLA molecule, typically wherein the cysteine is introduced into the CDR by mutation or modification of an existing residue.

IPC Classes  ?

• C12N 15/79 - Vectors or expression systems specially adapted for eukaryotic hosts
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/725 - T-cell receptors
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 38/00 - Medicinal preparations containing peptides